Caas Capital Management LP Inozyme Pharma, Inc. Transaction History

Caas Capital Management LP

  • $1.31 Billion
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$3.87 - $7.55 $437,662 - $853,837
-113,091 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$5.58 - $11.5 $124,473 - $256,530
-22,307 Reduced 16.48%
113,091 $771,000
Q3 2021

Nov 15, 2021
BUY
$11.12 - $19.4 $1.51 Million - $2.63 Million
135,398 New
135,398 $1.57 Million
Q2 2021

Aug 16, 2021
SELL
$15.19 - $21.2 $2.7 Million - $3.76 Million
-177,502 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$17.77 - $27.9 $3.15 Million - $4.95 Million
177,502 New
177,502 $3.52 Million

Others Institutions Holding INZY

# of Institutions
92
Shares Held
49M
Call Options Held
1.6K
Put Options Held
22K
View Full List

About Inozyme Pharma, Inc.

INZY Quotes by TradingView
  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $177M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email